Vanguard Group Inc. increased its position in LeMaitre Vascular Inc (NASDAQ:LMAT) by 0.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,336,600 shares of the medical instruments supplier’s stock after purchasing an additional 11,508 shares during the period. Vanguard Group Inc. owned about 0.07% of LeMaitre Vascular worth $37,398,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Conestoga Capital Advisors LLC boosted its stake in LeMaitre Vascular by 2.5% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,741,196 shares of the medical instruments supplier’s stock worth $48,719,000 after purchasing an additional 42,315 shares during the period. Copeland Capital Management LLC boosted its stake in LeMaitre Vascular by 150.7% in the 2nd quarter. Copeland Capital Management LLC now owns 386,557 shares of the medical instruments supplier’s stock worth $10,816,000 after purchasing an additional 232,351 shares during the period. Northern Trust Corp boosted its stake in LeMaitre Vascular by 0.5% in the 2nd quarter. Northern Trust Corp now owns 264,793 shares of the medical instruments supplier’s stock worth $7,408,000 after purchasing an additional 1,345 shares during the period. Bank of New York Mellon Corp boosted its stake in LeMaitre Vascular by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 262,851 shares of the medical instruments supplier’s stock worth $7,355,000 after purchasing an additional 8,942 shares during the period. Finally, Summit Creek Advisors LLC boosted its stake in LeMaitre Vascular by 0.3% in the 2nd quarter. Summit Creek Advisors LLC now owns 230,539 shares of the medical instruments supplier’s stock worth $6,450,000 after purchasing an additional 630 shares during the period. 78.60% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the stock. ValuEngine lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Monday, October 7th. Barrington Research reaffirmed an “outperform” rating and issued a $37.00 price objective (up previously from $32.00) on shares of LeMaitre Vascular in a research note on Thursday, July 25th. Lake Street Capital raised their price objective on shares of LeMaitre Vascular from $27.00 to $34.00 and gave the stock a “hold” rating in a research note on Thursday, July 25th. Zacks Investment Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 25th. Finally, BidaskClub raised shares of LeMaitre Vascular from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 13th. Four investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $36.50.

In other LeMaitre Vascular news, Director Michael H. Thomas sold 15,000 shares of LeMaitre Vascular stock in a transaction on Friday, August 9th. The shares were sold at an average price of $32.10, for a total transaction of $481,500.00. Following the completion of the sale, the director now owns 15,000 shares of the company’s stock, valued at approximately $481,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman George W. Lemaitre sold 66,037 shares of LeMaitre Vascular stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $34.45, for a total transaction of $2,274,974.65. Following the sale, the chairman now directly owns 3,171,124 shares of the company’s stock, valued at approximately $109,245,221.80. The disclosure for this sale can be found here. Insiders have sold a total of 129,654 shares of company stock valued at $4,423,865 in the last three months. Company insiders own 19.60% of the company’s stock.

Shares of NASDAQ:LMAT traded up $0.33 during trading on Wednesday, reaching $34.09. 4,868 shares of the company traded hands, compared to its average volume of 112,711. The firm has a fifty day simple moving average of $32.99 and a 200 day simple moving average of $29.96. The firm has a market cap of $668.75 million, a P/E ratio of 40.95, a price-to-earnings-growth ratio of 3.64 and a beta of 1.22. LeMaitre Vascular Inc has a 1-year low of $21.79 and a 1-year high of $36.06.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, July 24th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.02. The company had revenue of $29.48 million during the quarter, compared to analyst estimates of $28.90 million. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $0.43 EPS. As a group, research analysts anticipate that LeMaitre Vascular Inc will post 0.86 EPS for the current fiscal year.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Further Reading: What is a Futures Contract?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.